Suppr超能文献

静脉注射免疫球蛋白预防小儿艾滋病患者细菌感染

Intravenous immune globulin for prevention of bacterial infections in pediatric AIDS patients.

作者信息

Crow M E

机构信息

Campbell University, Department of Pharmacy Practice, Buies Creek, NC 27506, USA.

出版信息

Am J Health Syst Pharm. 1995 Apr 15;52(8):803-11. doi: 10.1093/ajhp/52.8.803.

Abstract

The immunologic and clinical abnormalities associated with pediatric human immunodeficiency virus (HIV) infection are reviewed, the rationale for using intravenous immune globulin (IVIG) to prevent serious bacterial infections is described, and clinical experience with IVIG for this indication is summarized. Immunologic and clinical abnormalities seen in pediatric HIV-infected patients differ from those seen in adult HIV-infected patients. In pediatric patients, impaired B-cell activity is an early and prominent manifestation of HIV infection. Infants infected with HIV do not develop the antigen-specific B- and T-cell clones required for immunologic memory, amplification, and production of specific antibodies. B-cell defects and lack of memory B cells result in a high rate of serious bacterial infections in HIV-infected children compared with adults. Natural killer cell dysfunction may also increase HIV-infected children's susceptibility to secondary infections. IVIG therapy in HIV-infected pediatric patients is based on evidence of impaired antibody function in these patients, although this use remains controversial. Case reports and one unblinded comparative study published during the 1980s suggest that IVIG may decrease morbidity and improve cellular and humoral immune response. One recent large-scale, double-blind, placebo-controlled study showed that IVIG 400 mg/kg every 28 days can decrease the morbidity associated with serious bacterial infections in HIV-infected children with CD4 cell counts of > 200 cells/cu mm. Another study involving HIV-infected children receiving concurrent zidovudine demonstrated that IVIG helped prevent serious bacterial infections in children who were not concurrently receiving trimethoprim-sulfamethoxazole but not in those who were. Although IVIG has not been shown to alter mortality in HIV-infected children, regular use may decrease the morbidity associated with serious bacterial infections.

摘要

本文回顾了与儿童人类免疫缺陷病毒(HIV)感染相关的免疫和临床异常情况,描述了使用静脉注射免疫球蛋白(IVIG)预防严重细菌感染的基本原理,并总结了IVIG用于该适应症的临床经验。儿童HIV感染患者中出现的免疫和临床异常情况与成人HIV感染患者不同。在儿童患者中,B细胞活性受损是HIV感染的早期突出表现。感染HIV的婴儿无法形成免疫记忆、扩增和产生特异性抗体所需的抗原特异性B细胞和T细胞克隆。与成人相比,B细胞缺陷和记忆B细胞的缺乏导致HIV感染儿童发生严重细菌感染的几率较高。自然杀伤细胞功能障碍也可能增加HIV感染儿童继发感染的易感性。HIV感染儿童患者的IVIG治疗基于这些患者抗体功能受损的证据,尽管这种用法仍存在争议。20世纪80年代发表的病例报告和一项非盲法对照研究表明,IVIG可能降低发病率并改善细胞和体液免疫反应。最近一项大规模、双盲、安慰剂对照研究表明,每28天静脉注射400mg/kg IVIG可降低CD4细胞计数>200个细胞/立方毫米的HIV感染儿童发生严重细菌感染的发病率。另一项涉及同时接受齐多夫定治疗的HIV感染儿童的研究表明,IVIG有助于预防未同时接受甲氧苄啶-磺胺甲恶唑治疗的儿童发生严重细菌感染,但对同时接受该治疗的儿童无效。尽管尚未证明IVIG可改变HIV感染儿童的死亡率,但定期使用可能降低与严重细菌感染相关的发病率。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验